WordNet

be a contributing factor; "make things factor into a companys profitability"
any of the numbers (or symbols) that form a product when multiplied together
an independent variable in statistics
anything that contributes causally to a result; "a number of factors determined the outcome"
consider as relevant when making a decision; "You must factor in the recent developments" (同)factor in, factor out
resolve into factors; "a quantum computer can factor the number 15" (同)factor in, factor out
an event known to have happened or something known to have existed; "your fears have no basis in fact"; "how much of the story is fact and how much fiction is hard to tell"
a concept whose truth can be proved; "scientific hypotheses are not facts"
a piece of information about circumstances that exist or events that have occurred; "first you must collect all the facts of the case"
a statement or assertion of verified information about something that is the case or has happened; "he supported his argument with an impressive array of facts"

PrepTutorEJDIC

(…の)『要因』,(…を生み出す)要素《+『in』+『名』(do『ing』)》 / 囲数,約数 / 代理人,《おもに英》仲買人 / =factorize
〈C〉『事実』,実際にある(あった)事 / 〈U〉真相,真実(truth) / 《the~》(法律用語で)犯行
Virgin Islands

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/08/14 18:01:02」(JST)

wiki en

Factor VII (EC 3.4.21.21, blood-coagulation factor VIIa, activated blood coagulation factor VII, formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. A recombinant form of human factor VIIa (eptacog alfa [activated], NovoSeven) has U.S. Food and Drug Administration approval for uncontrolled bleeding in hemophilia patients. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A biosimilar form of recombinant activated factor VII (AryoSeven) is also available, but does not play any considerable role in the market.

Physiology

The main role of factor VII (FVII) is to initiate the process of coagulation in conjunction with tissue factor (TF/factor III). Tissue factor is found on the outside of blood vessels - normally not exposed to the bloodstream. Upon vessel injury, tissue factor is exposed to the blood and circulating factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. The complex of factor VIIa with TF catalyzes the conversion of factor IX and factor X into the active proteases, factor IXa and factor Xa, respectively.^[2]

The action of the factor is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent; it is produced in the liver. Use of warfarin or similar anticoagulants decreases hepatic synthesis of FVII.

Genetics

The gene for factor VII is located on chromosome 13 (13q34).

Role in disease

Deficiency is rare (congenital proconvertin deficiency) and inherits recessively. Factor VII deficiency presents as a hemophilia-like bleeding disorder. It is treated with recombinant factor VIIa (NovoSeven or AryoSeven).

Medical uses

Recombinant factor VIIa, marketed under the trade names AryoSeven and NovoSeven, is used for people with hemophilia (with Factor VIII or IX deficiency) who have developed inhibitors against replacement coagulation factor.

It has also been used in the setting of uncontrollable hemorrhage,^[3] but its role in this setting is controversial with insufficient evidence to support its use outside of clinical trials.^[4] The first report of its use in hemorrhage was in an Israeli soldier with uncontrollable bleeding in 1999.^[5] Risks of its use include an increase in arterial thrombosis.^[4]

Recombinant human factor VII while initially looking promising in intracerebral hemorrhage failed to show benefit following further study and this is no longer recommended.^[6]^[7]

Interactions

Factor VII has been shown to interact with tissue factor.^[8]^[9]

References

^ Banner DW, D'Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D (1996). "The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor". Nature 380 (6569): 41–6. doi:10.1038/380041a0. PMID 8598903.
^ Wajima T, Isbister GK, Duffull SB (2009). "A comprehensive model for the humoral coagulation network in humans". Clin Pharmacol Ther 86 (3): 290–8. doi:10.1038/clpt.2009.87. PMID 19516255.
^ Roberts HR, Monroe DM, White GC (2004). "The use of recombinant factor VIIa in the treatment of bleeding disorders". Blood 104 (13): 3858–64. doi:10.1182/blood-2004-06-2223. PMID 15328151.
^ ^a ^b Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C (Mar 14, 2012). "Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.". Cochrane database of systematic reviews (Online) 3: CD005011. doi:10.1002/14651858.CD005011.pub4. PMID 22419303.
^ Kenet G, Walden R, Eldad A, Martinowitz U (1999). "Treatment of traumatic bleeding with recombinant factor VIIa". Lancet 354 (9193): 1879. doi:10.1016/S0140-6736(99)05155-7. PMID 10584732.
^ Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T (2005). "Recombinant activated factor VII for acute intracerebral hemorrhage". N. Engl. J. Med. 352 (8): 777–85. doi:10.1056/NEJMoa042991. PMID 15728810.
^ Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T (May 2008). "Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage". N. Engl. J. Med. 358 (20): 2127–37. doi:10.1056/NEJMoa0707534. PMID 18480205.
^ Carlsson K, Freskgård PO, Persson E, Carlsson U, Svensson M (Jun 2003). "Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor". Eur. J. Biochem. 270 (12): 2576–82. doi:10.1046/j.1432-1033.2003.03625.x. PMID 12787023.
^ Zhang E, St Charles R, Tulinsky A (Feb 1999). "Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant". J. Mol. Biol. 285 (5): 2089–104. doi:10.1006/jmbi.1998.2452. PMID 9925787.

External links

Official website
The MEROPS online database for peptidases and their inhibitors: S01.215

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非血友病患者における遺伝子組換え第VIIa凝固因子の治療使用 therapeutic uses of recombinant coagulation factor viia in non hemophiliacs
2. 稀な遺伝性凝固異常 rare inherited coagulation disorders
3. 止血の概要 overview of hemostasis
4. 後天性の凝固因子阻害物質 acquired inhibitors of coagulation
5. Management of stress ulcers

English Journal

Review article: update in trauma anesthesiology: perioperative resuscitation management.

Tobin JM, Varon AJ.SourceUniversity of Maryland/R Adams Cowley Shock Trauma Center, 22 South Greene St., T1R77, Baltimore, MD 21201. josh_tobin@hotmail.co.
Anesthesia and analgesia.Anesth Analg.2012 Dec;115(6):1326-33. doi: 10.1213/ANE.0b013e3182639f20. Epub 2012 Jul 4.
The management of trauma patients has matured significantly since a systematic approach to trauma care was introduced nearly a half century ago. The resuscitation continuum emphasizes the effect that initial therapy has on the outcome of the trauma patient. The initiation of this continuum begins wi
PMID 22763906

Japanese Journal

血液凝固第VII 因子の構造と機能および臨床応用

日本血栓止血学会誌 26(5), 562-575, 2015
NAID 130005102999

A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease

The Tohoku Journal of Experimental Medicine 237(1), 45-50, 2015
NAID 130005096764

Is thrombin a "toxin" in the pathogenesis of preeclampsia?

Hypertension Research in Pregnancy 3(1), 13-18, 2015
NAID 130005093543

Related Pictures

★リンクテーブル★

リンク元	「活性化第VII因子」
拡張検索	「coagulation factor VIIa」
関連記事	「fact」「factor」

「活性化第VII因子」

Coagulation factor VII (serum prothrombin conversion accelerator)
	Anchoring of coagulation factor VIIa (PDB 1dan) to the membrane through its Gla domain
Available structures
PDB	Ortholog search: PDBe, RCSB
List of PDB id codes
	1BF9, 1CVW, 1DAN, 1DVA, 1F7E, 1F7M, 1FAK, 1FF7, 1FFM, 1J9C, 1JBU, 1KLI, 1KLJ, 1NL8, 1O5D, 1QFK, 1W0Y, 1W2K, 1W7X, 1W8B, 1WQV, 1WSS, 1WTG, 1WUN, 1WV7, 1YGC, 1Z6J, 2A2Q, 2AEI, 2AER, 2B7D, 2B8O, 2BZ6, 2C4F, 2EC9, 2F9B, 2FIR, 2FLB, 2FLR, 2PUQ, 2ZP0, 2ZWL, 2ZZU, 3ELA, 3TH2, 3TH3, 3TH4, 4IBL, 4ISH, 4ISI, 4JYU, 4JYV, 4JZD, 4JZE, 4JZF, 4NA9, 4NG9, 4NGA, 4X8S, 4X8T, 4X8U, 4X8V, 4YT6, 4YT7
Identifiers
Symbols	F7 ; SPCA
External IDs	OMIM: 613878 MGI: 109325 HomoloGene: 7710 ChEMBL: 3991 GeneCards: F7 Gene
EC number	3.4.21.21
Gene ontology
Molecular function	• glycoprotein binding; • serine-type endopeptidase activity; • receptor binding; • calcium ion binding; • protein binding; • serine-type peptidase activity;
Cellular component	• extracellular region; • extracellular space; • endoplasmic reticulum lumen; • Golgi lumen; • plasma membrane; • vesicle;
Biological process	• positive regulation of leukocyte chemotaxis; • proteolysis; • blood coagulation; • blood coagulation, extrinsic pathway; • circadian rhythm; • positive regulation of platelet-derived growth factor receptor signaling pathway; • peptidyl-glutamic acid carboxylation; • positive regulation of blood coagulation; • positive regulation of cell migration; • organ regeneration; • response to vitamin K; • response to estrogen; • post-translational protein modification; • cellular protein metabolic process; • positive regulation of positive chemotaxis; • positive regulation of protein kinase B signaling; • response to growth hormone;
	Sources: Amigo / QuickGO
RNA expression pattern
	More reference expression data
Orthologs
	v; t; e;